Limited Offer
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code needed.
Advances in Viral Hepatitis B and D: Moving Toward the Goals of Elimination., An Issue of Clinics in Liver Disease
- 1st Edition, Volume 27-4 - October 4, 2023
- Editor: Robert G. Gish
- Language: English
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 9 3 9 4 7 - 8
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 3 9 4 8 - 5
In this issue of Clinics in Liver Disease, guest editor Robert G. Gish brings his considerable expertise to the topic of Hepatitis B and Hepatitis D. The articles provide state… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteIn this issue of Clinics in Liver Disease, guest editor Robert G. Gish brings his considerable expertise to the topic of Hepatitis B and Hepatitis D. The articles provide state-of-the-art clinical summaries of the advances in Hepatitis B and D, with emphasis on HBV viro-immunology, novel assays, new targets, and tests for HBV and HDV, and more.
Contains 13 relevant, practice-oriented topics including Novel Assays to Solve the Clinical and Scientific Challenges of Chronic Hepatitis B; Maternal-to-Child Transmission of Hepatitis B Virus and Hepatitis Delta Virus; Triple Threat: HDV, HBV, HIV Coinfection; Targeting Hepatitis B Virus DNA Using Designer Gene Editors; and more.
Provides in-depth clinical reviews on Hepatitis B and D, offering actionable insights for clinical practice.
Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Forthcoming Issues
- Preface
- Hepatitis B
- Chronic Hepatitis B: Treat all Who Are Viremic?
- Key points
- Introduction
- Natural history of chronic hepatitis B
- Benefits of expanding treatment eligibility
- Conclusion-is it time to adopt a treat all approach?
- Clinics care points
- Declaration of funding Sources
- Declaration of personal interests
- Authors’ contributions and authorship Statement
- Are the New Nucleos(t)ide Analogs Better than the Old Nucleos(t)ide Analogs?
- Key points
- Introduction
- Virological response and drug-resistance
- ALT normalization
- Long-term safety of nucleos(t)ide analog agent treatments
- Ecological studies for the mortality by liver disease and liver cancer
- Hepatocellular carcinoma risk: entecavir versus lamivudine or adefovir (ADV)
- Hepatocellular carcinoma risk: entecavir versus tenofovir disoproxil fumarate
- Hepatocellular carcinoma risk: tenofovir alafenamide versus tenofovir disoproxil fumarate
- Hepatocellular carcinoma recurrence: entecavir versus tenofovir disoproxil fumarate
- Summary
- Conflict of interests
- Role of funding source
- What Is the Current Status of Hepatitis B Virus Viro-Immunology?
- Key points
- Introduction
- The natural history of hepatitis B virus infection is closely dependent on the dynamic interplay between the host immune response and viral replication
- Viral features and genotypes
- Immunologic impairment in chronic hepatitis B virus infection
- Final remarks
- Clinics care points
- Disclosure
- Novel Assays to Solve the Clinical and Scientific Challenges of Chronic Hepatitis B
- Key points
- Introduction
- Hepatitis B infection
- Current methods for diagnosis and clinical monitoring of hepatitis B
- Unresolved clinical issues
- Unresolved scientific issues for cure research
- Summary
- Clinics care points
- Conflict of interest
- Funding
- Overview of New Targets for Hepatitis B Virus: Immune Modulators, Interferons, Bifunctional Peptides, Therapeutic Vaccines and Beyond
- Key points
- Introduction
- Viral life cycle
- Antiviral strategies
- Immunomodulatory strategies
- Summary
- Clinics care points
- Conflict of interest statement
- Novel Drug Development in Chronic Hepatitis B Infection: Capsid Assembly Modulators and Nucleic Acid Polymers
- Key points
- Overview
- Hepatitis B surface antigen release inhibitor: nucleic acid polymers/S-antigen transport-inhibiting oligonucleotide polymers
- Capsid assembly modulators
- Summary
- Clinics care points
- Disclosure
- Targeting Hepatitis B Virus DNA Using Designer Gene Editors
- Key points
- Introduction
- Molecular tools for gene editing
- Results of hepatitis B virus DNA cleavage
- Antiviral effect of nucleases against hepatitis B virus
- Alternate approaches to target hepatitis B virus DNA
- Targeting cellular genes
- Barriers and solutions to using nucleases for therapy
- Summary
- Clinics care points
- Disclosure
- funding
- Delta Hepatitis
- Maternal-to-Child Transmission of Hepatitis B Virus and Hepatitis Delta Virus
- Key points
- Introduction
- Epidemiology of hepatitis B virus and hepatitis delta virus in women of childbearing age and in pregnancy
- Hepatitis B virus in pregnancy
- Maternal-to-child transmission of hepatitis B virus
- Effects on infected infants
- Hepatitis delta virus in pregnancy
- Management of hepatitis B virus and hepatitis delta virus in pregnancy
- Summary
- Disclosure
- Clinics care points
- State of the Art: Test all for Anti-Hepatitis D Virus and Reflex to Hepatitis D Virus RNA Polymerase Chain Reaction Quantification
- Key points
- Introduction/history/definition/background
- Disease states of hepatitis D virus
- Acute hepatitis D virus: coinfection pattern
- Acute hepatitis D virus: superinfection pattern
- Chronic hepatitis D infection
- Features of hepatitis D antigen
- Hepatitis D virus testing and diagnosis
- Reverse transcription-polymerase chain reaction assays
- Reliability of reverse transcription-polymerase chain reaction and issues with genetic heterogeneity
- Genotyping assays
- Barriers to testing
- Endpoints in clinical trials and disease monitoring
- Assays predicting therapeutic response
- Future diagnostic tests for hepatitis D virus
- Summary and conclusion
- Clinics care points
- Disclosure
- Triple Threat: HDV, HBV, HIV Coinfection
- Key points
- Introduction
- Hepatitis delta virus virology and immunology in the setting of HIV
- Hepatitis delta virus epidemiology and natural history in HIV patients
- Liver cancer due to hepatitis delta virus in HIV patients
- Screening and diagnosis in people living with HIV
- Unique treatment considerations
- Summary
- Clinics care points
- What Is the Real Epidemiology of Hepatitis D Virus and Why so Many Mixed Messages?
- Key points
- Manuscript body
- Clinics care points
- Disclosure
- What is the Path Forward to Treat Hepatitis Delta Virus?: Old Treatments and New Options
- Key points
- Introduction
- Old treatments
- Should we use analogues for hepatitis B virus treatment ?
- Summary
- Clinics care points
- Authors' contributions
- Conflicts of interest
- Back to “B”
- Test All for Hepatitis B Virus: Link to Care and Treatment if Quantitative DNA Positive, Vaccinate if Susceptible
- Key points
- Introduction
- Discussion
- Summary
- Clinics care points
- Disclosures
- Funding
- No. of pages: 240
- Language: English
- Edition: 1
- Volume: 27-4
- Published: October 4, 2023
- Imprint: Elsevier
- Hardback ISBN: 9780323939478
- eBook ISBN: 9780323939485
RG
Robert G. Gish
Affiliations and expertise
Professor Medicine at Loma Linda University, Adjunct Professor of Medicine at the University of Nevada , School of Medicine in Las Vegas, Clinical Professor at the University of Nevada Reno School of Medicine, Clinical Professor at the University of California Skaggs School of Pharmacy and Pharmaceutical Sciences